Related Experiment Video
Updated: Mar 5, 2026

Frailty Assessment in an Aging Mouse Model
Published on: September 23, 2025
A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention
Jonathan Karnon1,2, Hossein Haji Ali Afzali3,4, Gregorius Virgianto Arpuji Anggoro Putro3
1School of Public Health, University of Adelaide, Adelaide, SA, 5005, Australia. jonathan.karnon@adelaide.edu.au.
A new cost-effectiveness model predicts long-term health costs and quality-adjusted life years (QALYs) for frail Australians. A physiotherapy intervention shows value for money, costing $8129 per QALY gained.
Area of Science:
- Gerontology
- Health Economics
- Public Health
Background:
- The clinical significance of frailty is growing, necessitating long-term economic evaluations of interventions.
- Existing economic studies on frailty management often have limited time horizons.
- This research addresses the need for lifetime cost and outcome predictions in frail populations.
Purpose of the Study:
- To develop a cost-effectiveness model for predicting lifetime costs and quality-adjusted life years (QALYs) in frail Australians.
- To conduct a model-based cost-utility analysis of a physiotherapy intervention for frail individuals.
Main Methods:
- A cohort-based state transition (Markov) model was created to predict lifetime costs and QALYs.
- The model incorporates health states for frailty, residential status, bone fractures, depression, and mortality.
- Input parameters were derived from the Dynamic Analyses to Optimise Ageing dataset and literature.
Main Results:
- The developed cost-effectiveness model underwent validation and proved reliable.
- A physiotherapy intervention for frailty yielded an incremental cost of Australian $8129 per QALY gained compared to usual care.
- There is a 30% probability that usual care is more cost-effective than the physiotherapy intervention.
Conclusions:
- Frailty significantly impacts quality of life and incurs substantial management costs, with increasing prevalence.
- New frailty management strategies must demonstrate economic value.
- The cost-effectiveness model provides a framework for evaluating interventions and informing funding decisions in Australia.
More Related Videos
Related Concept Videos
Pharmacodynamics in Geriatric Patients: Effects of Age
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

